$HAREHOLDER INVESTIGATION: The M&A Class Action Firm Is Investigating the Merger: SSBK, LNSR, iCAD and BSGM
Law Firm Overview: Monteverde & Associates PC, a recognized class action firm based in New York, is investigating several proposed mergers involving Southern States Bancshares, LENSAR, iCAD, and BioSig Technologies, offering free consultations for shareholders concerned about these transactions.
Shareholder Votes: Upcoming shareholder votes for the mentioned companies are scheduled between June 26 and July 14, 2025, with specific terms outlined for each merger agreement.
Trade with 70% Backtested Accuracy
Analyst Views on LNSR
About LNSR
About the author
Elizabeth O'Farrell Joins the Board of Directors at SpyGlass Pharma
Appointment Announcement: SpyGlass Pharma has appointed Elizabeth O'Farrell as an Independent Director and Chair of the Audit Committee, effective immediately.
Experience and Role: Ms. O'Farrell brings over 30 years of experience in strategic planning, financial optimization, and regulatory compliance, which will aid SpyGlass in advancing its Drug Delivery Platform through pivotal Phase 3 trials.
Background: O'Farrell previously held several executive roles at Eli Lilly, including CFO and Chief Procurement Officer, and currently serves on multiple boards, providing her with extensive finance and operational expertise.
SpyGlass Pharma Overview: The company is focused on developing a controlled release drug delivery platform for glaucoma management, aiming for FDA approval after successful clinical trials.
Elizabeth O’Farrell Joins the Board of Directors at SpyGlass Pharma
Appointment Announcement: SpyGlass Pharma has appointed Elizabeth (Liz) O’Farrell as an Independent Director and Chair of the Audit Committee, effective immediately.
Experience and Role: Ms. O’Farrell brings over 30 years of experience in strategic planning, financial optimization, and regulatory compliance, which will aid SpyGlass as it advances its Drug Delivery Platform into Phase 3 trials.
Background: She previously held various executive positions at Eli Lilly, including CFO of Lilly USA and Chief Procurement Officer, and currently serves on multiple boards, providing valuable insights to those organizations.
SpyGlass Pharma Overview: The company is focused on developing a controlled release drug delivery platform for glaucoma management, with plans to share follow-up data from its studies at an upcoming ophthalmology meeting.
